Financial reports
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
27 Feb 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
10-Q
2021 Q3
Quarterly report
8 Nov 21
10-Q
2021 Q2
Quarterly report
12 Aug 21
Current reports
8-K
Termination of a Material Definitive Agreement
11 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
3 Aug 23
8-K
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
28 Jul 23
8-K
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days
20 Jun 23
8-K
Departure of Directors or Certain Officers
15 Jun 23
8-K
Other Events
12 Jun 23
8-K
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
12 Jun 23
8-K
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
9 May 23
8-K
Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors
13 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
Registration and prospectus
15-12G
Securities registration termination
21 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
Proxies
DEFA14A
Additional proxy soliciting materials
1 Aug 23
DEFA14A
Additional proxy soliciting materials
26 Jul 23
DFAN14A
Additional proxy materials by non-management
10 Jul 23
DEFM14A
Proxy related to merger
10 Jul 23
PREM14A
Preliminary proxy related to merger
27 Jun 23
DEFA14A
Additional proxy soliciting materials
20 Jun 23
DEFA14A
Additional proxy soliciting materials
14 Jun 23
DEFA14A
Additional proxy soliciting materials
12 Jun 23
DEFA14A
Additional proxy soliciting materials
12 Jun 23
DFAN14A
Additional proxy materials by non-management
12 Jun 23
Other
EFFECT
Notice of effectiveness
17 Aug 23
EFFECT
Notice of effectiveness
15 Apr 21
CORRESP
Correspondence with SEC
12 Apr 21
UPLOAD
Letter from SEC
12 Apr 21
EFFECT
Notice of effectiveness
27 Aug 20
CORRESP
Correspondence with SEC
24 Aug 20
CORRESP
Correspondence with SEC
24 Aug 20
UPLOAD
Letter from SEC
4 Aug 20
CT ORDER
Confidential treatment order
19 Mar 19
CT ORDER
Confidential treatment order
12 Apr 18
Ownership
SC 13D/A
Samsara BioCapital, L.P.
22 Nov 23
SC 13D
Farallon Capital Partners, L.P.
11 Aug 23
4
Dolca Thomas
11 Aug 23
4
Andrew Oxtoby
11 Aug 23
4
Mahesh Krishnan
11 Aug 23
4
Andrew James King
11 Aug 23
4
MICHELLE RENEE GRIFFIN
11 Aug 23
4
William Mariner Greenman
11 Aug 23
4
Tom Frohlich
11 Aug 23
4
ERIC DOBMEIER
11 Aug 23